TipRanks
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
US Market
TSHA
Taysha Gene Therapies
RESEARCH TOOLSreports
Want to see TSHA full AI Analyst Report?

Taysha Gene Therapies (TSHA) Stock Forecast & Price Target

1,292 Followers
See the Price Targets and Ratings of:

TSHA Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Taysha
Gene Therapies
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TSHA Stock 12 Month Forecast

Average Price Target

$14.00
▲(132.56% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Taysha Gene Therapies in the last 3 months. The average price target is $14.00 with a high forecast of $19.00 and a low forecast of $11.00. The average price target represents a 132.56% change from the last price of $6.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","11":"$11","20":"$20","6.5":"$6.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.5,11,15.5,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,5.836923076923077,6.933846153846154,8.03076923076923,9.127692307692307,10.224615384615385,11.321538461538461,12.418461538461539,13.515384615384615,14.612307692307692,15.70923076923077,16.806153846153848,17.903076923076924,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,5.452307692307692,6.164615384615384,6.876923076923077,7.5892307692307694,8.301538461538462,9.013846153846155,9.726153846153846,10.438461538461539,11.150769230769232,11.863076923076923,12.575384615384616,13.287692307692309,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,5.2215384615384615,5.703076923076924,6.184615384615385,6.666153846153846,7.147692307692308,7.6292307692307695,8.11076923076923,8.592307692307692,9.073846153846155,9.555384615384614,10.036923076923078,10.518461538461539,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.33,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.86,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$19.00Average Price Target$14.00Lowest Price Target$11.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on TSHA
Biren Amin
Piper Sandler
Piper Sandler
$12
Buy
99.34%
Upside
Reiterated
10/16/26
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), PROCEPT BioRobotics (PRCT)
Wolfe Research Analyst forecast on TSHA
Kalpit Patel
Wolfe Research
Wolfe Research
―
Buy
―
Initiated
09/17/26
Taysha Gene Therapies initiated with an Outperform at Wolfe ResearchTaysha Gene Therapies initiated with an Outperform at Wolfe Research
Bank of America Securities Analyst forecast on TSHA
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/14/26
Analysts Are Bullish on Top Healthcare Stocks: Evotec AG (EVO), Taysha Gene Therapies (TSHA)
Wells Fargo Analyst forecast on TSHA
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$11
Buy
82.72%
Upside
Assigned
08/12/26
Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)
Needham Analyst forecast on TSHA
Gil Blum
Needham
Needham
$12
Buy
99.34%
Upside
Reiterated
08/12/26
Gil Blum Reaffirms Buy Rating on Taysha Gene Therapies, Maintains $12 Price Target Amid De-Risking Clinical Milestones
Cantor Fitzgerald Analyst forecast on TSHA
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$19
Buy
215.61%
Upside
Reiterated
08/11/26
Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)
Goldman Sachs Analyst forecast on TSHA
Salveen Richter
Goldman Sachs
Goldman Sachs
$13
Buy
115.95%
Upside
Reiterated
08/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Canaccord Genuity Analyst forecast on TSHA
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$17
Buy
182.39%
Upside
Reiterated
08/11/26
Canaccord Reaffirms Buy on Taysha Gene Therapies as Pivotal Trials Advance and $17 Price Target Backed by Strong Cash Runway
BMO Capital Analyst forecast on TSHA
Evan Seigerman
BMO Capital
BMO Capital
$14
Buy
132.56%
Upside
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Taysha Gene Therapies (NASDAQ: TSHA) and Zymeworks (NASDAQ: ZYME)
Robert W. Baird Analyst forecast on TSHA
Jack Allen
Robert W. Baird
Robert W. Baird
$12→$15
Buy
149.17%
Upside
Reiterated
06/30/26
Taysha Gene Therapies price target raised to $15 from $12 at BairdTaysha Gene Therapies price target raised to $15 from $12 at Baird
Jefferies Analyst forecast on TSHA
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$13
Buy
115.95%
Upside
Reiterated
06/23/26
Jefferies Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)
Citizens JMP Analyst forecast on TSHA
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$8→$11
Buy
82.72%
Upside
Reiterated
06/23/26
Taysha Gene Therapies price target raised to $11 from $8 at CitizensTaysha Gene Therapies price target raised to $11 from $8 at Citizens
Chardan Capital Analyst forecast on TSHA
Geulah Livshits
Chardan Capital
Chardan Capital
$12
Buy
99.34%
Upside
Reiterated
05/06/26
Chardan Capital Remains a Buy on Taysha Gene Therapies (TSHA)
Raymond James Analyst forecast on TSHA
Christopher Raymond
Raymond James
Raymond James
$13
Buy
115.95%
Upside
Reiterated
11/25/25
Raymond James Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)
UBS Analyst forecast on TSHA
Joon Lee
UBS
UBS
―
Buy
―
Reiterated
11/05/25
Taysha Gene Therapies (TSHA) Receives a Rating Update from a Top Analyst
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on TSHA
Biren Amin
Piper Sandler
Piper Sandler
$12
Buy
99.34%
Upside
Reiterated
10/16/26
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), PROCEPT BioRobotics (PRCT)
Wolfe Research Analyst forecast on TSHA
Kalpit Patel
Wolfe Research
Wolfe Research
―
Buy
―
Initiated
09/17/26
Taysha Gene Therapies initiated with an Outperform at Wolfe ResearchTaysha Gene Therapies initiated with an Outperform at Wolfe Research
Bank of America Securities Analyst forecast on TSHA
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/14/26
Analysts Are Bullish on Top Healthcare Stocks: Evotec AG (EVO), Taysha Gene Therapies (TSHA)
Wells Fargo Analyst forecast on TSHA
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$11
Buy
82.72%
Upside
Assigned
08/12/26
Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)
Needham Analyst forecast on TSHA
Gil Blum
Needham
Needham
$12
Buy
99.34%
Upside
Reiterated
08/12/26
Gil Blum Reaffirms Buy Rating on Taysha Gene Therapies, Maintains $12 Price Target Amid De-Risking Clinical Milestones
Cantor Fitzgerald Analyst forecast on TSHA
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$19
Buy
215.61%
Upside
Reiterated
08/11/26
Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)
Goldman Sachs Analyst forecast on TSHA
Salveen Richter
Goldman Sachs
Goldman Sachs
$13
Buy
115.95%
Upside
Reiterated
08/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Canaccord Genuity Analyst forecast on TSHA
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$17
Buy
182.39%
Upside
Reiterated
08/11/26
Canaccord Reaffirms Buy on Taysha Gene Therapies as Pivotal Trials Advance and $17 Price Target Backed by Strong Cash Runway
BMO Capital Analyst forecast on TSHA
Evan Seigerman
BMO Capital
BMO Capital
$14
Buy
132.56%
Upside
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Taysha Gene Therapies (NASDAQ: TSHA) and Zymeworks (NASDAQ: ZYME)
Robert W. Baird Analyst forecast on TSHA
Jack Allen
Robert W. Baird
Robert W. Baird
$12→$15
Buy
149.17%
Upside
Reiterated
06/30/26
Taysha Gene Therapies price target raised to $15 from $12 at BairdTaysha Gene Therapies price target raised to $15 from $12 at Baird
Jefferies Analyst forecast on TSHA
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$13
Buy
115.95%
Upside
Reiterated
06/23/26
Jefferies Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)
Citizens JMP Analyst forecast on TSHA
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$8→$11
Buy
82.72%
Upside
Reiterated
06/23/26
Taysha Gene Therapies price target raised to $11 from $8 at CitizensTaysha Gene Therapies price target raised to $11 from $8 at Citizens
Chardan Capital Analyst forecast on TSHA
Geulah Livshits
Chardan Capital
Chardan Capital
$12
Buy
99.34%
Upside
Reiterated
05/06/26
Chardan Capital Remains a Buy on Taysha Gene Therapies (TSHA)
Raymond James Analyst forecast on TSHA
Christopher Raymond
Raymond James
Raymond James
$13
Buy
115.95%
Upside
Reiterated
11/25/25
Raymond James Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)
UBS Analyst forecast on TSHA
Joon Lee
UBS
UBS
―
Buy
―
Reiterated
11/05/25
Taysha Gene Therapies (TSHA) Receives a Rating Update from a Top Analyst
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
ONCBeOne Medicines
IRLAIRulya Therapeutics
IDYAIDEAYA Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Taysha Gene Therapies

3 Months
Gil BlumNeedham
Success Rate
16/30 ratings generated profit
53%
Average Return
+3.44%
Copying Gil Blum's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +3.44% per trade.
1 Year
Joon LeeUBS
Success Rate
13/22 ratings generated profit
59%
Average Return
+59.19%
Copying Joon Lee's trades and holding each position for 1 Year would result in 59.09% of your transactions generating a profit, with an average return of +59.19% per trade.
2 Years
Joon LeeUBS
Success Rate
15/22 ratings generated profit
68%
Average Return
+57.52%
Copying Joon Lee's trades and holding each position for 2 Years would result in 68.18% of your transactions generating a profit, with an average return of +57.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TSHA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
17
16
17
8
7
Buy
1
1
1
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
17
18
10
9
In the current month, TSHA has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TSHA average Analyst price target in the past 3 months is 14.00.
Each month's total comprises the sum of three months' worth of ratings.

TSHA Financial Forecast

TSHA Earnings Forecast

Next quarter’s earnings estimate for TSHA is -$0.13 with a range of -$0.14 to -$0.11. The previous quarter’s EPS was -$0.13. TSHA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TSHA has Performed in-line its overall industry.
Next quarter’s earnings estimate for TSHA is -$0.13 with a range of -$0.14 to -$0.11. The previous quarter’s EPS was -$0.13. TSHA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TSHA has Performed in-line its overall industry.

TSHA Sales Forecast

Next quarter’s sales forecast for TSHA is $756.00K with a range of $0.00 to $3.80M. The previous quarter’s sales results were $0.00. TSHA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TSHA has Performed in-line its overall industry.
Next quarter’s sales forecast for TSHA is $756.00K with a range of $0.00 to $3.80M. The previous quarter’s sales results were $0.00. TSHA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TSHA has Performed in-line its overall industry.

TSHA Stock Forecast FAQ

What is TSHA’s average 12-month price target, according to analysts?
Based on analyst ratings, Taysha Gene Therapies’s 12-month average price target is 14.00.
    What is TSHA’s upside potential, based on the analysts’ average price target?
    Taysha Gene Therapies has 132.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TSHA a Buy, Sell or Hold?
          Taysha Gene Therapies has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Taysha Gene Therapies’s price target?
            The average price target for Taysha Gene Therapies is 14.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $19.00 ,the lowest forecast is $11.00. The average price target represents 132.56% Increase from the current price of $6.02.
              What do analysts say about Taysha Gene Therapies?
              Taysha Gene Therapies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of TSHA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.